Price data is not available
InMed Pharmaceuticals Inc
INMNASDAQ
InMed Pharmaceuticals rose 759.7% from $1.81 to $15.56, ahead of the S&P 500's +12.7%. Its worst day was Nov 5 (−20.9%), and its low came Mar 30 at $0.62.
Nov 13, 2025 – Nov 6, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.51 was reported on $820,188.00 revenue.
−10.1% · S&P 500 −1.5%
InMed Pharmaceuticals closed at its lowest level of the year, 66.0% below where the year started.
Story events cover the past 12 months · Times ET
−6.2% · S&P 500 −0.3%
EPS of $-0.69 was reported on $659,848.00 revenue.
−4.1% · S&P 500 −0.3%
EPS of $-1.20 was reported on $576,339.00 revenue.
0.0% · S&P 500 −0.6%
EPS of $-0.36 was reported on $0.00 revenue.
+3.1% · S&P 500 +0.3%
Where it ended: a close of $15.56 on Nov 6, 2026. Up next: Q2 2027 earnings on Feb 10, 2027.
Nothing in the past 12 months.
All INM analyst actionsNothing in the past 12 months.
All INM dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for INM and SPY from Benzinga historical bars. Not investment advice.
